

Supplementary Table 3. Interobserver Agreement for LI-RADS Treatment Response Features on Gadoteric Acid-Enhanced MRI

	Proportion of Agreement	Kappa Value
No lesional enhancement	83/105 (79.0)	0.473
Treatment-specific expected enhancement	88/105 (83.9)	0.469
NMLIT with APHE on ordinary arterial-phase images	93/105 (88.6)	0.750
NMLIT with APHE on arterial subtraction images	94/105 (89.5)	0.790
NMLIT with washout appearance	84/105 (80.0)	0.524
NMLIT with enhancement similar to pretreatment imaging	95/105 (90.5)	0.722
Final LR-TR category on ordinary arterial-phase images	81/105 (77.1)	0.597
Final LR-TR category on arterial subtraction images	85/105 (81.0)	0.661
Size of viable or equivocally viable lesion, mm	NA	0.842*

Unless otherwise indicated, data are number (%) of lesions. *Agreement was evaluated using the intraclass correlation coefficient. APHE = arterial phase hyperenhancement, LI-RADS = Liver Imaging Reporting and Data System, LR-TR = LI-RADS treatment response, NA = not applicable, NMLIT = nodular, mass-like, or irregular thick tissue in or along the treated lesion